Mer­ck’s Keytru­da sales eclipse $18B on the year, while num­bers for Lagevrio sur­prise

Mer­ck’s block­buster can­cer drug Keytru­da made $18.4 bil­lion in the first nine months of the year — near­ly the same amount as the re­port­ed rev­enue of the NFL in 2022.

In the third quar­ter of 2023, Mer­ck re­port­ed $6.3 bil­lion in Keytru­da sales, slight­ly high­er than Wall Street ex­pec­ta­tions. Mer­ck ex­pects about 20% of its Keytru­da sales this year to come from ear­li­er-stage can­cer in­di­ca­tions, chief fi­nan­cial of­fi­cer Car­o­line Litch­field said in an an­a­lyst call Thurs­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER